Carboplatin and etoposide in previously treated colorectal cancer patients

G. Colucci, E. Maiello, F. Giuliani, R. A. Cifarelli, F. Giotta

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aims and background: Salvage treatment of advanced colorectal cancer patients has not been well defined as yet, and new potentially active drugs or combinations should be evaluated for these situations. Methods: From February 1993 to September 1993, the combination of carboplatin (CBDCA) and etoposide (VP-16), both as 100 mg/m2 for three consecutive days, was administered to 17 colorectal cancer patients who had been previously subjected to FA-FU combination chemotherapy. The CBDCA+VP-16 treatment was repeated every 3 weeks. A total of 58 cycles was administered, and 16 patients were evaluable for response. Results: There was no objective response, but 2 stable diseases and 14 progressive diseases were observed. Toxicity was mild, with no WHO 3-4 grade toxicity. Conclusion: this combination chemotherapy was judged ineffective for pretreated colorectal cancer patients.

Original languageEnglish
Pages (from-to)36-38
Number of pages3
JournalTumori
Volume81
Issue number1
Publication statusPublished - 1995

Fingerprint

Carboplatin
Etoposide
Colorectal Neoplasms
Combination Drug Therapy
Salvage Therapy
Drug Combinations
Therapeutics

Keywords

  • carboplatin + etoposide chemotherapy
  • colorectal cancer
  • salvage treatment

ASJC Scopus subject areas

  • Cancer Research

Cite this

Carboplatin and etoposide in previously treated colorectal cancer patients. / Colucci, G.; Maiello, E.; Giuliani, F.; Cifarelli, R. A.; Giotta, F.

In: Tumori, Vol. 81, No. 1, 1995, p. 36-38.

Research output: Contribution to journalArticle

@article{c64c1399720e4dd4b94f64d2e40e6c77,
title = "Carboplatin and etoposide in previously treated colorectal cancer patients",
abstract = "Aims and background: Salvage treatment of advanced colorectal cancer patients has not been well defined as yet, and new potentially active drugs or combinations should be evaluated for these situations. Methods: From February 1993 to September 1993, the combination of carboplatin (CBDCA) and etoposide (VP-16), both as 100 mg/m2 for three consecutive days, was administered to 17 colorectal cancer patients who had been previously subjected to FA-FU combination chemotherapy. The CBDCA+VP-16 treatment was repeated every 3 weeks. A total of 58 cycles was administered, and 16 patients were evaluable for response. Results: There was no objective response, but 2 stable diseases and 14 progressive diseases were observed. Toxicity was mild, with no WHO 3-4 grade toxicity. Conclusion: this combination chemotherapy was judged ineffective for pretreated colorectal cancer patients.",
keywords = "carboplatin + etoposide chemotherapy, colorectal cancer, salvage treatment",
author = "G. Colucci and E. Maiello and F. Giuliani and Cifarelli, {R. A.} and F. Giotta",
year = "1995",
language = "English",
volume = "81",
pages = "36--38",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Carboplatin and etoposide in previously treated colorectal cancer patients

AU - Colucci, G.

AU - Maiello, E.

AU - Giuliani, F.

AU - Cifarelli, R. A.

AU - Giotta, F.

PY - 1995

Y1 - 1995

N2 - Aims and background: Salvage treatment of advanced colorectal cancer patients has not been well defined as yet, and new potentially active drugs or combinations should be evaluated for these situations. Methods: From February 1993 to September 1993, the combination of carboplatin (CBDCA) and etoposide (VP-16), both as 100 mg/m2 for three consecutive days, was administered to 17 colorectal cancer patients who had been previously subjected to FA-FU combination chemotherapy. The CBDCA+VP-16 treatment was repeated every 3 weeks. A total of 58 cycles was administered, and 16 patients were evaluable for response. Results: There was no objective response, but 2 stable diseases and 14 progressive diseases were observed. Toxicity was mild, with no WHO 3-4 grade toxicity. Conclusion: this combination chemotherapy was judged ineffective for pretreated colorectal cancer patients.

AB - Aims and background: Salvage treatment of advanced colorectal cancer patients has not been well defined as yet, and new potentially active drugs or combinations should be evaluated for these situations. Methods: From February 1993 to September 1993, the combination of carboplatin (CBDCA) and etoposide (VP-16), both as 100 mg/m2 for three consecutive days, was administered to 17 colorectal cancer patients who had been previously subjected to FA-FU combination chemotherapy. The CBDCA+VP-16 treatment was repeated every 3 weeks. A total of 58 cycles was administered, and 16 patients were evaluable for response. Results: There was no objective response, but 2 stable diseases and 14 progressive diseases were observed. Toxicity was mild, with no WHO 3-4 grade toxicity. Conclusion: this combination chemotherapy was judged ineffective for pretreated colorectal cancer patients.

KW - carboplatin + etoposide chemotherapy

KW - colorectal cancer

KW - salvage treatment

UR - http://www.scopus.com/inward/record.url?scp=0029059082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029059082&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 36

EP - 38

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -